AbbVie (ABBV) Invested Capital (2012 - 2026)

AbbVie (ABBV) has reported Invested Capital for 15 consecutive years, with $64.9 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Invested Capital fell 12.24% year-over-year to $64.9 billion in Q2 2026; TTM through Jun 2026 was $64.9 billion, a 12.24% decrease from a year earlier, with the FY2025 full-year figure at $64.2 billion, down 8.91% from the prior year.
• Invested Capital was $64.9 billion for Q2 2026 at AbbVie, down from $66.2 billion in the prior quarter.
• Over five years, Invested Capital peaked at $89.8 billion in Q1 2022 and troughed at $64.2 billion in Q4 2025.
• A 5-year average of $75.1 billion and a median of $73.9 billion in 2023 frame the typical range for Invested Capital.
• Across the five-year window, Invested Capital fell 16.03% in 2023 and increased 8.82% in 2024, its largest moves.
• Over 5 years, Invested Capital stood at $80.6 billion in 2022, then dropped by 13.38% to $69.8 billion in 2023, then increased by 1.04% to $70.5 billion in 2024, then fell by 8.91% to $64.2 billion in 2025, then grew by 1.03% to $64.9 billion in 2026.
• The last three Invested Capital figures came in at $64.9 billion (Q2 2026), $66.2 billion (Q1 2026), and $64.2 billion (Q4 2025), per Business Quant data.